The Longevity Consortium received a five-year, $45 million grant to move the consortium’s work to its next stage: integrating results from numerous studies about the factors that contribute to longer and healthier lives.
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations.
